PDL BioPharma (PDLI) Earns Media Impact Rating of 0.14
Media headlines about PDL BioPharma (NASDAQ:PDLI) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. PDL BioPharma earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.0597462405109 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of PDL BioPharma (NASDAQ PDLI) opened at $3.04 on Friday. The stock has a market capitalization of $468.41, a price-to-earnings ratio of 6.33 and a beta of 0.45. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.94 and a quick ratio of 1.90. PDL BioPharma has a one year low of $1.93 and a one year high of $3.77.
PDL BioPharma (NASDAQ:PDLI) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.01. The firm had revenue of $62.75 million for the quarter, compared to analyst estimates of $61.86 million. PDL BioPharma had a return on equity of 9.33% and a net margin of 24.51%. The business’s revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 earnings per share. equities research analysts predict that PDL BioPharma will post 0.69 EPS for the current year.
PDL BioPharma declared that its Board of Directors has authorized a stock buyback plan on Monday, September 25th that authorizes the company to repurchase $25.00 million in shares. This repurchase authorization authorizes the biotechnology company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.
A number of research analysts have recently weighed in on the company. ValuEngine upgraded PDL BioPharma from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Cowen and Company restated a “hold” rating and issued a $3.00 target price on shares of PDL BioPharma in a report on Friday, October 27th. Zacks Investment Research upgraded PDL BioPharma from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Wednesday, August 16th. Piper Jaffray Companies restated a “buy” rating and issued a $4.00 target price on shares of PDL BioPharma in a report on Thursday, August 10th. Finally, BidaskClub upgraded PDL BioPharma from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $3.33.
PDL BioPharma Company Profile
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.